A Case of Plaque Psoriasis Successfully Treated with Ixekizumab Following Secukinumab Failure
Secukinumab 치료 실패 후 ixekizumab으로 성공적으로 치료된 판상 건선 1예
- Document Type
- Publications · Journal Article
- Registered DB
- KCI
- Journal
- 대한건선학회지18(2) · pp.54 · 2021
- Citation
- KCI 1
- ISSN
- 2384-1176
Authors
- Jisang YunFirst author부산대학교병원 피부과학교실
- 김성준아름다운피부과의원
- Bae, Kyung Nam부산대학교병원
- Son, Jin-Hwa부산대학교병원
- Shin, Kihyuk부산대학교병원
- Kim, Hoon-soo부산대학교병원 피부과학교실
- Ko, Hyun-Chang부산대학교병원 피부과학교실
- Kim, Moon-Bum부산대학교병원 피부과학교실
- Kim, ByungsooCorresponding author부산대학교
Abstract
If there is no improvement of the lesion despite the use of a biological agent, a change to another agent may be considered, and successful ‘intra-class switching’ has been reported. The reason for the effect of changes within the same class is explained as different depending on the molecular structure and pharmacokinetic characteristics of the drug. Pharmacokinetics may show differences in molecular affinity and half-life. Herein, we report a case of successful treatment with ixekizumab, the same IL-17A inhibitor class drug, after secukinumab treatment failure. The patient was diagnosed with psoriasis on histological examination, and treatment with secukinumab was started in November 2017. However, from the 5th month onwards, there was an insufficient response, and psoriasis worsened, and the treatment was judged as a failure and then stopped. Ixekizumab was started in December 2019, and almost all lesions have improved and remained stable thereafter.
Keywords
Identifiers
- KCI
- ART002795488



Login
Back to Publication list